5 Key Takeaways
-
1
Bausch + Lomb's TENEO excimer laser is the first FDA-approved excimer platform in nearly 20 years, enhancing LASIK surgery for myopia and myopic astigmatism.
-
2
Operating at 1,740Hz, TENEO features the fastest eye-tracker on the market, improving precision and potentially leading to quicker recovery for patients.
-
3
The TENEO platform eliminates the need for a nomogram, reducing surgical planning time and minimizing the risk of transcription errors.
-
4
A multicenter study showed that 97.8% of eyes achieved uncorrected distance visual acuity of 20/25 or better after using the TENEO laser.
-
5
TENEO's compact design enhances ergonomics for surgeons and patient comfort, making it easier to integrate into clinical settings.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.